Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System.

Buxbaum JN, Johansson J.

Front Neurosci. 2017 Mar 15;11:119. doi: 10.3389/fnins.2017.00119. eCollection 2017. Review.

2.

Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.

Sant'Anna R, Almeida MR, Varejāo N, Gallego P, Esperante S, Ferreira P, Pereira-Henriques A, Palhano FL, de Carvalho M, Foguel D, Reverter D, Saraiva MJ, Ventura S.

Sci Rep. 2017 Mar 24;7:44709. doi: 10.1038/srep44709.

3.

Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.

Sartiani L, Bucciantini M, Spinelli V, Leri M, Natalello A, Nosi D, Maria Doglia S, Relini A, Penco A, Giorgetti S, Gerace E, Mannaioni G, Bellotti V, Rigacci S, Cerbai E, Stefani M.

Biophys J. 2016 Nov 1;111(9):2024-2038. doi: 10.1016/j.bpj.2016.09.010.

PMID:
27806283
4.

The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa.

Jacobson DR, Alexander AA, Tagoe C, Garvey WT, Williams SM, Tishkoff S, Modiano D, Sirima SB, Kalidi I, Toure A, Buxbaum JN.

Mol Genet Genomic Med. 2016 Jul 14;4(5):548-56. doi: 10.1002/mgg3.231. eCollection 2016 Sep.

5.

Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation.

Schrader T, Bitan G, Klärner FG.

Chem Commun (Camb). 2016 Oct 15;52(76):11318-34. doi: 10.1039/c6cc04640a. Epub 2016 Aug 22.

6.

Current and future treatment of amyloid diseases.

Ankarcrona M, Winblad B, Monteiro C, Fearns C, Powers ET, Johansson J, Westermark GT, Presto J, Ericzon BG, Kelly JW.

J Intern Med. 2016 Aug;280(2):177-202. doi: 10.1111/joim.12506. Epub 2016 May 10.

PMID:
27165517
7.

Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy.

García-Lezana T, Oria M, Romero-Giménez J, Bové J, Vila M, Genescà J, Chavarria L, Cordoba J.

J Cereb Blood Flow Metab. 2017 Mar;37(3):927-937. doi: 10.1177/0271678X16649196. Epub 2016 Jul 20.

PMID:
27154504
8.

Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer.

Iakovleva I, Begum A, Brännström K, Wijsekera A, Nilsson L, Zhang J, Andersson PL, Sauer-Eriksson AE, Olofsson A.

PLoS One. 2016 Apr 19;11(4):e0153529. doi: 10.1371/journal.pone.0153529. eCollection 2016.

9.

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.

Sant'Anna R, Gallego P, Robinson LZ, Pereira-Henriques A, Ferreira N, Pinheiro F, Esperante S, Pallares I, Huertas O, Almeida MR, Reixach N, Insa R, Velazquez-Campoy A, Reverter D, Reig N, Ventura S.

Nat Commun. 2016 Feb 23;7:10787. doi: 10.1038/ncomms10787.

10.

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P.

Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Review.

11.

Uncovering the Mechanism of Aggregation of Human Transthyretin.

Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio D, Ruchala P, Whitelegge J, Jiang L, Riek R, Eisenberg DS.

J Biol Chem. 2015 Nov 27;290(48):28932-43. doi: 10.1074/jbc.M115.659912. Epub 2015 Oct 12.

12.

Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis.

Castaño A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, Bettencourt B, Gollob J, Karsten V, Vest JA, Chiuzan C, Maurer MS, Bokhari S.

J Nucl Cardiol. 2016 Dec;23(6):1355-1363. Epub 2015 Oct 9.

13.

Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.

McWilliams-Koeppen HP, Foster JS, Hackenbrack N, Ramirez-Alvarado M, Donohoe D, Williams A, Macy S, Wooliver C, Wortham D, Morrell-Falvey J, Foster CM, Kennel SJ, Wall JS.

PLoS One. 2015 Sep 22;10(9):e0137716. doi: 10.1371/journal.pone.0137716. eCollection 2015.

14.

Amyloid Oligomers and Mature Fibrils Prepared from an Innocuous Protein Cause Diverging Cellular Death Mechanisms.

Harte NP, Klyubin I, McCarthy EK, Min S, Garrahy SA, Xie Y, Davey GP, Boland JJ, Rowan MJ, Mok KH.

J Biol Chem. 2015 Nov 20;290(47):28343-52. doi: 10.1074/jbc.M115.676072. Epub 2015 Jul 28.

15.

Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils.

Groenning M, Campos RI, Hirschberg D, Hammarström P, Vestergaard B.

Sci Rep. 2015 Jun 25;5:11443. doi: 10.1038/srep11443.

16.

The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response.

Iakovleva I, Begum A, Pokrzywa M, Walfridsson M, Sauer-Eriksson AE, Olofsson A.

PLoS One. 2015 May 28;10(5):e0128222. doi: 10.1371/journal.pone.0128222. eCollection 2015.

17.

Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out.

Chen JJ, Genereux JC, Wiseman RL.

IUBMB Life. 2015 Jun;67(6):404-13. doi: 10.1002/iub.1386. Epub 2015 May 26. Review.

18.

Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis.

Akasaki Y, Reixach N, Matsuzaki T, Alvarez-Garcia O, Olmer M, Iwamoto Y, Buxbaum JN, Lotz MK.

Arthritis Rheumatol. 2015 May;67(8):2097-107. doi: 10.1002/art.39178.

19.

A loss of FUS/TLS function leads to impaired cellular proliferation.

Ward CL, Boggio KJ, Johnson BN, Boyd JB, Douthwright S, Shaffer SA, Landers JE, Glicksman MA, Bosco DA.

Cell Death Dis. 2014 Dec 11;5:e1572. doi: 10.1038/cddis.2014.508.

20.

ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.

Chen JJ, Genereux JC, Qu S, Hulleman JD, Shoulders MD, Wiseman RL.

Chem Biol. 2014 Nov 20;21(11):1564-74. doi: 10.1016/j.chembiol.2014.09.009. Epub 2014 Oct 23.

Supplemental Content

Support Center